Advertisement

Topics

Insys Eyes Sale of Opioid-Related Assets, Including Subsys

19:00 EST 8 Nov 2018 | BioSpace

Months after the U.S. Food and Drug Administration (FDA) rejected Insys Therapeutics’ buprenorphine sublingual spray for moderate-to-severe acute pain, the Arizona-based company is assessing strategic alternatives for its opioid-related assets as it continues to shift its focus to a new therapeut...

Original Article: Insys Eyes Sale of Opioid-Related Assets, Including Subsys

NEXT ARTICLE

More From BioPortfolio on "Insys Eyes Sale of Opioid-Related Assets, Including Subsys"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pain Disorder
Pain is a feeling (sharp or dull) triggered in the nervous system which can be transient or constant. Pain can be specific to one area of the body eg back, abdomen or chest or more general all over the body eg muscles ache from the flu. Without pain ...